Holen Sie sich die Stockscreener-App
9.56
4.40%
-0.44
Handel nachbörslich:
9.56
Schlusskurs vom Vortag:
$10.00
Offen:
$10
24-Stunden-Volumen:
41,970
Relative Volume:
0.44
Marktkapitalisierung:
$248.08M
Einnahmen:
$26.00M
Nettoeinkommen (Verlust:
$-219.71M
KGV:
-0.192
EPS:
-49.8
Netto-Cashflow:
$-51.37M
1W Leistung:
+4.37%
1M Leistung:
-19.66%
6M Leistung:
-49.23%
1J Leistung:
-69.59%
1-Tages-Spanne:
$9.36
$10.02
1-Wochen-Bereich:
$8.46
$10.10
52-Wochen-Spanne:
$8.46
$41.87
Cartesian Therapeutics Inc Stock (RNAC) Company Profile
Firmenname
Cartesian Therapeutics Inc
Sektor
Branche
Telefon
301-348-8698
Adresse
7495 NEW HORIZON WAY, FREDERICK
Vergleichen Sie RNAC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RNAC
Cartesian Therapeutics Inc
|
9.56 | 237.74M | 26.00M | -219.71M | -51.37M | -49.80 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Cartesian Therapeutics Inc Stock (RNAC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-19 | Eingeleitet | BTIG Research | Buy |
| 2024-08-06 | Eingeleitet | TD Cowen | Buy |
| 2024-07-02 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-06-04 | Eingeleitet | Oppenheimer | Outperform |
| 2024-05-24 | Eingeleitet | Mizuho | Buy |
| 2024-04-23 | Bestätigt | H.C. Wainwright | Buy |
| 2024-04-23 | Eingeleitet | Leerink Partners | Outperform |
| 2023-08-18 | Herabstufung | SVB Securities | Outperform → Market Perform |
| 2022-06-14 | Bestätigt | Needham | Buy |
| 2022-06-06 | Eingeleitet | SVB Leerink | Outperform |
| 2021-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-01-26 | Hochstufung | Mizuho | Neutral → Buy |
| 2020-10-01 | Herabstufung | Mizuho | Buy → Neutral |
| 2020-10-01 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2020-06-12 | Herabstufung | Stifel | Buy → Hold |
| 2020-04-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-01-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-01-21 | Eingeleitet | William Blair | Outperform |
| 2018-06-27 | Eingeleitet | Janney | Buy |
| 2017-03-30 | Bestätigt | UBS | Buy |
Alle ansehen
Cartesian Therapeutics Inc Aktie (RNAC) Neueste Nachrichten
Cartesian Therapeutics Enrolls First Participant in Phase 3 Myasthenia Gravis Study - marketscreener.com
Cartesian Therapeutics Announces First Participant Enrolled - GlobeNewswire
RNAC Initiates Phase 3 Trial for Myasthenia Gravis Treatment | R - GuruFocus
RNAC Initiates Phase 3 Trial for Myasthenia Gravis Treatment | RNAC Stock News - GuruFocus
Cartesian Therapeutics Announces First Participant Enrolled in t - GuruFocus
Cartesian Therapeutics Initiates Phase 3 AURORA Trial of Descartes-08 for Myasthenia Gravis - Nasdaq
Cartesian Therapeutics Announces First Participant Enrolled in the Phase 3 AURORA Trial of Descartes-08 in Patients with Myasthenia Gravis - Yahoo Finance
With Trials In Motion, Cash To 2027, Can Kyverna's Next Data Drop Turn The Stock Around? - Benzinga
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Holdings Lifted by Northern Trust Corp - Defense World
Q1 Earnings Forecast for RNAC Issued By HC Wainwright - Defense World
HC Wainwright Has Bearish Forecast for RNAC Q2 Earnings - Defense World
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Multiple Myeloma Pipeline 2025: Groundbreaking Clinical - openPR.com
Cantor Fitzgerald Comments on RNAC FY2025 Earnings - Defense World
Cartesian Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ - The Manila Times
Cartesian Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor ... - Eagle-Tribune
Wells Fargo & Company MN Acquires 2,568 Shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World
Cartesian Therapeutics (RNAC) Poised for Growth with Strong Phas - GuruFocus
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates - Yahoo Finance
Barclays PLC Buys 7,488 Shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World
MetLife Investment Management LLC Invests $119,000 in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World
Cartesian Therapeutics First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Needham & Company LLC Has Lowered Expectations for Cartesian Therapeutics (NASDAQ:RNAC) Stock Price - Defense World
Analysts Are Bullish on Top Healthcare Stocks: Harrow Health (HROW), Cartesian Therapeutics (RNAC) - The Globe and Mail
Cartesian Therapeutics Reports Q1 2025 Financial Results - TipRanks
Needham Maintains Buy Rating on RNAC, Lowers Price Target | RNAC Stock News - GuruFocus
RNAC Reports Strong Q1 Revenue Exceeding Expectations | RNAC Stock News - GuruFocus
Cartesian Therapeutics Inc (RNAC) Q1 2025 Earnings: EPS Loss of $(0.68) Beats Estimate, Revenue Surpasses Forecast at $1.1 Million - GuruFocus
Cartesian Therapeutics Announces Upcoming Clinical Trials and Positive Results for Descartes-08 in Autoimmune Diseases - Nasdaq
Cartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
Cartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire Inc.
Renaissance Technologies LLC Buys New Holdings in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World
Why Cartesian Therapeutics, Inc. (RNAC) is Among the Best Small Cap Stocks to Buy with the Biggest Upside Potential - Insider Monkey
Subdued Growth No Barrier To Cartesian Therapeutics, Inc. (NASDAQ:RNAC) With Shares Advancing 27% - simplywall.st
Top 11 Small Cap Stocks to Buy with Biggest Upside Potential - Insider Monkey
Cartesian Therapeutics Announces New Employment Inducement Grants | RNAC Stock News - GuruFocus
Cartesian Therapeutics (RNAC) Issues Inducement Awards to New Em - GuruFocus
Cartesian Therapeutics Announces New Employment Inducement Grants - The Manila Times
Cartesian Therapeutics Expands Clinical Team: 27,700 Shares Granted to New Biotech Experts - Stock Titan
Cartesian Therapeutics CTO transitions to consultant role By Investing.com - Investing.com India
Cartesian Therapeutics CTO transitions to consultant role - Investing.com
Cartesian Therapeutics CTO Transition to Consultant Role - TipRanks
SEC Form DEF 14A filed by Cartesian Therapeutics Inc. - Quantisnow
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Shares Purchased by Geode Capital Management LLC - Defense World
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives $42.67 Consensus Target Price from Brokerages - Defense World
Cartesian Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update - ADVFN
Cartesian Therapeutics’ mRNA CAR-T Descartes-08 Shows Efficacy and Safety in Myasthenia Gravis in Phase 2 Study - CGTLive®
JPMorgan Chase & Co. Sells 34,278 Shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World
After-Market Momentum Builds For ASP Isotopes (ASPI) Amid Secondary Listing News - Stocks Telegraph
Corebridge Financial Inc. Increases Holdings in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World
Cartesian Therapeutics’ (RNAC) Buy Rating Reiterated at Needham & Company LLC - Defense World
Finanzdaten der Cartesian Therapeutics Inc-Aktie (RNAC)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.89%
3.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):